
S2Ep10: Interview with Dr. Maria Deza Leon
This interview followed a Keynote speech Dr. Deza Leon gave at the 2026 Hawk Talks Event at KU Edwards Campus on May 1.
Show notes
Hosted by Jack Treml · 🇺🇸 US · EN · 21 episodes
Established thought leaders with verified media credentials.
Reprogrammed in a biotechnology podcast that explores a new topic every season through examining a series of seminal papers. This podcast supports a Selected Topics in Biotechnology course at the University of Kansas' Edwards Campus - but you don't need to be in that course to listen!
Jack Treml hosts Reprogrammed: A biotechnology Podcast, a education show with 21 episodes published.

This interview followed a Keynote speech Dr. Deza Leon gave at the 2026 Hawk Talks Event at KU Edwards Campus on May 1.
Show notes
This episode looks at two papers, one a 2019 paper by Hassett et al. about optimizing Lipid Nanoparticles specifically for intramuscular mRNA vaccines. And a second, Laczko et al., from 2020, that shows what kind of immu
Show notes
This episode discusses the 2005 Kariko et al. paper about RNA immunogenicity.
Show notes
In this episode, we explain why influenza is such a persistent threat—its segmented RNA genome enables antigenic drift and reassortment-driven “shift,” letting it change faster than traditional vaccines can be manufactur
Show notes
mRNA vaccines: when the call is coming from inside the house, discusses how the immune system knows what's going on inside of cells and how specific that knowledge is. This episode explains MHC Haplotype and how MHC rest
Show notes
This episode explores an early mRNA vaccination study showing that injected RNA can be injected into the body, be translated into protein that is presented on MHC class I to generate an antigen-specific cytotoxic T-cell
Show notes
This week on Reprogrammed, Jack and Annie tackle a key limitation in CAR T cell therapy for solid tumors: poor trafficking to the tumor site. Centered on the 2010 study by Craddock et al., this episode explores how engin
Show notes
In this episode, we examine the work of Roselli et al.1, who explore a critical frontier in CAR T cell engineering: how to build T cells that don’t just kill tumors effectively, but also survive, persist, and adapt in th
Show notes
Over the past episodes of Reprogrammed, we’ve followed the rapid evolution of CAR T cell therapy—from early experiments demonstrating that antibody-based chimeric receptors could trigger T cell activation and IL-2 produc
Show notes
Over the past episodes of Reprogrammed, we’ve followed the rapid evolution of CAR T cell therapy—from early experiments demonstrating that antibody-based chimeric receptors could trigger T cell activation and IL-2 produc
Show notes
Reprogrammed is a biotechnology podcast exploring the development of cell therapies, with this season focusing on CAR T cells in cancer treatment. The Brentjens et al. (2013) study marked a pivotal moment in the clinical
Show notes
This podcast delves into the exciting world of cancer immunotherapy, focusing on the evolution of cancer vaccines and the recent surge of cell-based therapies. This series follows a string of primary research papers high
Show notes
This podcast delves into the exciting world of cancer immunotherapy, focusing on the evolution of cancer vaccines and the recent surge of cell-based therapies. This series follows a string of primary research papers high
Show notes
This podcast delves into the exciting world of cancer immunotherapy, focusing on the evolution of cancer vaccines and the recent surge of cell-based therapies. This series follows a string of primary research papers high
Show notes
This is the first paper to demonstrate that plasmid DNA injections elicited humoral immune responses and could therefore function as vaccines.
Show notes
This episode addresses the question of whether lymphocytes can be harvested, reprogrammed in their specificity for a selected tumor antigen ex vivo, and then re-administered to the patient to combat their cancer. The fir
Show notes
This episode addresses the question of whether lymphocytes directed against one specific tumor antigen can be manipulated to better combat cancer. The first paper, from 1989, examines cells initially generated in an anim
Show notes
Introduction of key papers:o 1974 article by Israel Penn, MD, on cancer in immune deficiencies.2020 article by Hegde et al. on dendritic cells and immune surveillance.• Framing question: “Does the immune system operate t
Show notes
This podcast delves into the exciting world of cancer immunotherapy, focusing on the evolution of cancer vaccines and the recent surge of cell-based therapies. It begins with a brief historical overview, highlighting the
Show notes
This episode relates to: the 1990 Wolff et al., paper in Science,247(4949 Pt 1):1465–1468. Direct Gene Transfer into Mouse Muscle in Vivo and the 1993 Ulmer et al., paper in Science, 259(5102):1745–1749. Heterologous pro
Show notesSponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.






To pitch Reprogrammed: A biotechnology Podcast, visit https://podcasters.spotify.com/pod/show/jack-treml for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent education coverage.
Reprogrammed: A biotechnology Podcast is hosted by Jack Treml. The show is categorised under education and has published 21 episodes.
Reprogrammed: A biotechnology Podcast has published 21 episodes.
Reprogrammed: A biotechnology Podcast regularly covers education. It sits in the education category.
Reprogrammed: A biotechnology Podcast is accessible for guests with genuine education expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Reprogrammed: A biotechnology Podcast hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Reprogrammed: A biotechnology Podcast average 19 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Reprogrammed: A biotechnology Podcast's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 12 days ago.